Summary by Futu AI
HUTCHMED WILL ANNOUNCE THE TOP LINE AND SUBGROUP RESULTS OF THE SOLOPINIB ESLIM-01 PHASE III STUDY AT THE EUROPEAN BLOOD ASSOCIATION ANNUAL MEETING IN MADRID, SPAIN, FROM 13 TO 16 JUNE 2024. The study, a Phase III clinical trial in China in patients with primary immunodeficiency, showed that solepinib has a clinically meaningful rapid and sustained platelet count response. In addition, the company will publish the latest clinical data for other blood malignant tumor therapies. Wah Wong Pharmaceuticals is a biopharmaceutical company focused on the treatment of cancer and immune diseases, which has marketed three drugs in China and the United States.